Pulmozyme — CareFirst (Caremark)

Initial criteria

• Diagnosis of cystic fibrosis
• Pulmozyme will be used in conjunction with standard therapies for cystic fibrosis

Reauthorization criteria

• Member is experiencing benefit from therapy as evidenced by disease stability or disease improvement
• Indication remains cystic fibrosis as listed in coverage criteria

Approval duration

12 months